ACELRX PHARMACEUTICALS INC Form SC 13G/A February 17, 2015
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SCHEDULE 13G/A (Amendment No. 2)
Under the Securities Exchange Act of 1934
AcelRx Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00444T100
(CUSIP Number)
December 31, 2014
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
xRule 13d-1(b) oRule 13d-1(c) oRule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 00444T100 13G/A Page 2 of 7 Pages

names of reporting persons

i.r.s. identification no. of above persons (entities only)

1.

Perceptive Advisors LLC

2. check the appropriate box if a group* (b) o sec use only

3.

citizenship or place of organization

4. Delaware, United States of America

number of 5. sole voting power shares beneficially 6. shared voting power 6,574,060 owned by each 7. sole dispositive power 0 reporting person 8. shared dispositive power 6,574,060 with: aggregate amount beneficially 9. owned by each reporting 6,574,060 person check box if the aggregate amount in row (9) excludes 10. o certain shares (See Instructions) percent of class represented by 15.04% 11. amount in row (9) type of reporting person (See 12. Instructions)

CUSIP No. 00444T100 13G/A Page 3 of 7 Pages

names of reporting persons

i.r.s. identification no. of above persons (entities only)

13.

Joseph Edelman

check the appropriate box if a group*

(a) o
(b) o
sec use only

15.

citizenship or place of organization

16. United States of America

number of 17. sole voting power 0 shares beneficially 18. shared voting power 6,574,060 owned by each 19. sole dispositive power 0 reporting person 20. shared dispositive power 6,574,060 with: aggregate amount beneficially owned by each reporting person 6,574,060 21. check box if the aggregate 22. amount in row (9) excludes certain shares (See Instructions) percent of class represented by 15.04% 23. amount in row (9) type of reporting person (See 24. IN Instructions)

CUSIP No. 00444T100 13G/A Page 4 of 7 Pages

Item 1.

(a) Name of Issuer: AcelRx Pharmaceuticals, Inc.

Address of Issuer's Principal

351 Galveston Drive

Executive

Redwood City, CA 94063 Offices:

Item 2.

This Schedule 13G/A (the "Schedule") is being filed with respect to shares of Common Stock (as defined below) of AcelRx Pharmaceuticals, Inc.

(a) Name of Person Filing:

(the "Issuer") which are beneficially owned by

Perceptive Advisors LLC and Joseph Edelman (together, the "Reporting Persons"). See Item

4 below.

Address of

499 Park Avenue, 25th Floor

Principal Business

Office or, if none, Residence:

New York, NY 10022

Perceptive Advisors LLC is a

Delaware limited liability (c) Citizenship:

company and Joseph Edelman

is a United States Citizen.

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number: 00444T100

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (i) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

CUSIP No. 00444T100 13G/A Page 5 of 7 Pages

Item 4. Ownership.

Amount

owned:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

The Reporting Persons beneficially own a total of 6,574,060 shares of Common Stock held by a private investment fund to which (a) beneficially Perceptive Advisors LLC serves as the investment manager. Mr. Edelman is the managing member of Perceptive Advisors LLC. The beneficial ownership of 15.04% is based on the Issuer's

(b) Percent of class:

Common Stock as disclosed on the Issuer's Form 10-Q filed with the SEC on November 10, 2014.

43,707,390 outstanding

shares of

Number of shares

(c) as to which the

person has:

(i) Sole power 0 to vote or

to direct the vote: Shared power to (ii) vote or to 6,574,060 direct the vote: Sole power to dispose or to direct 0 (iii) the disposition of: Shared power to dispose or (iv) to direct 6,574,060 the disposition of:

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o.

Item 6 Ownership of More Than Five Percent on Behalf of Another Person

The Fund described in Item 4 has the right to receive or the power to direct the receipt of dividends from, or the proceeds from, the sale of the securities held in its account. Filing of this statement by the Reporting Persons shall not be deemed an admission that they beneficially own the securities reported herein. The Reporting Persons expressly disclaim beneficial ownership of all securities reported herein.

Item Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by theParent Holding Company or Control Person.

Not applicable.

CUSIP No. 00444T100 13G/A Page 6 of 7 Pages

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification

The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

CUSIP No. 00444T100 13G/A Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2015

Date

PERCEPTIVE ADVISORS LLC

/s/ Joseph Edelman

Signature

Joseph Edelman/Managing Member

Name/Title

February 17, 2015

Date

/s/ Joseph Edelman

Signature

Joseph Edelman

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)